The material on this site is for financial institutions, professional investors and their professional advisers. It is for information only. Please read our Terms & Conditions, Privacy Policy and Cookies before using this site. Please see our Subscription Terms and Conditions.

All material subject to strictly enforced copyright laws. © 2022 Euromoney, a part of the Euromoney Institutional Investor PLC.

Zentiva livens up Prague exchange

The Prague Stock Exchange, which had been more or less comatose for years, sprang into life thanks to the $211 million IPO from generic drugs maker Zentiva. It was the first IPO on the exchange for a decade.

The deal was lead managed internationally by Merrill Lynch, and locally by Wood & Co. It was priced at Kc485, at the high end of the original price talk of Kc400 to Kc525 and it traded up about 5% in first trading.

Ian Carton, managing director of ECM at Merrill Lynch, says the international book included emerging-market investors but also healthcare investors. ?Generic drug manufacturers are the sweet spot of pharmaceuticals right now,? he says.

The company has the best brand recognition of any pharma in the Czech and Slovak republics, partly because it used to be a state company, called Leciva. It was bought in 1998 in a management buyout.

About 20% of the deal was sold to Czechs. The IPO was an important event for the exchange, which has become accustomed to delistings rather than new issues. About 1,500 companies were required to list, of which more than 1,000 later delisted. Some foreign companies that bought Czech firms have also delisted their acquisitions, to avoid problems with minority investors.

You have reached premium content. Please log in to continue reading.

Read beyond the headlines with Euromoney

For over 50 years, our readers have looked to Euromoney to stay informed about the issues that matter in the international banking and financial markets. Find out more about our different levels of access below.


Unlimited access to and

Expert comment, long reads and in-depth analysis interviews with senior finance professionals

Access the results of our market-leading annual surveys across core financial services

Access the results of our annual awards, including the world-renowned Awards for Excellence

Your print copy of Euromoney magazine delivered monthly

£73.75 per month

Billed Annually


Unlimited access to and, including our top stories, long reads, expert analysis, and the results of our annual surveys and awards

Sign up to any of our newsletters, curated by our editors


Already a user?

We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree